The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IACH Focus on Leukemia 2020 | Understanding disease biology of AML to develop targeted therapies
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses how understanding disease biology is crucial for the development of new targeted therapies. Prof. Nagler outlines that specific mutations were discovered in acute myeloid leukemia (AML); these were P53 and MP1. Additionally, other aspects of biology are important for drug development as well, such as the role of the microenvironment. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
